.png)
.png)
Arecor receives regulatory approval to initiate phase I clinical trial for ultra-rapid acting insulin product
Arecor Limited, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, today announces that a Phase I Clinical Trial Application (“CTA”) for product candidate AT247 has been approved by the Bundesamt für Sicherheit im Gesundheitswesen (BASG), the Austrian Federal Office for Safety in Health Care.
Arecor’s AT247, is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. Prandial insulin is used in the management of diabetes to control the rise in blood glucose after meals. The novel formulation of AT247 is designed to deliver an acceleration of insulin absorption post injection. This enables more effective management of blood glucose levels to ensure lower variability of post-meal blood glucose elevations and the potential clinical benefits of avoiding both hypoglycaemia and hyperglycaemia.
The double-blind, randomised, three-way cross over study will compare the pharmacokinetic and pharmacodynamic profiles of AT247 to current best in class insulin treatments. The trial is being conducted in Austria at an internationally recognised centre of excellence in the field of diabetes research.
Sarah Howell, Chief Executive Officer at Arecor said, "We are pleased that the CTA has been approved to enable a clinical study of AT247. We believe that this product candidate meets a recognised need to develop faster acting insulins to further improve the lives of people managing Type I diabetes. This is an important milestone for Arecor and we look forward to providing further updates as AT247 progresses through clinical development.”
For more information, please contact:
Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: [email protected]
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: [email protected]
PeckwaterPR www.peckwaterpr.co.uk
Tarquin Edwards Mob : +44 (0) 7879 458 364
Email : [email protected]
About Arecor
Arecor Limited is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
• Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
• Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices,
• Stable aqueous glucagon for emergency and artificial pancreas use, and
• A series of undisclosed pre-clinical programmes.
In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Arecor’s AT247, is an ultra-rapid acting prandial insulin product candidate targeting improved treatment for people living with Type I diabetes. Prandial insulin is used in the management of diabetes to control the rise in blood glucose after meals. The novel formulation of AT247 is designed to deliver an acceleration of insulin absorption post injection. This enables more effective management of blood glucose levels to ensure lower variability of post-meal blood glucose elevations and the potential clinical benefits of avoiding both hypoglycaemia and hyperglycaemia.
The double-blind, randomised, three-way cross over study will compare the pharmacokinetic and pharmacodynamic profiles of AT247 to current best in class insulin treatments. The trial is being conducted in Austria at an internationally recognised centre of excellence in the field of diabetes research.
Sarah Howell, Chief Executive Officer at Arecor said, "We are pleased that the CTA has been approved to enable a clinical study of AT247. We believe that this product candidate meets a recognised need to develop faster acting insulins to further improve the lives of people managing Type I diabetes. This is an important milestone for Arecor and we look forward to providing further updates as AT247 progresses through clinical development.”
For more information, please contact:
Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: [email protected]
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: [email protected]
PeckwaterPR www.peckwaterpr.co.uk
Tarquin Edwards Mob : +44 (0) 7879 458 364
Email : [email protected]
About Arecor
Arecor Limited is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
• Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
• Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices,
• Stable aqueous glucagon for emergency and artificial pancreas use, and
• A series of undisclosed pre-clinical programmes.
In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.